Krystal Biotech (KRYS) – Research Analysts’ Weekly Ratings Changes

Krystal Biotech (NASDAQ: KRYS) recently received a number of ratings updates from brokerages and research firms:

• 12/18/2024 – Krystal Biotech had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
• 12/18/2024 – Krystal Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
• 12/12/2024 – Krystal Biotech had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
• 12/10/2024 – Krystal Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
• 11/5/2024 – Krystal Biotech had its price target raised by analysts at Citigroup Inc. from $204.00 to $206.00. They now have a “neutral” rating on the stock.
• 11/5/2024 – Krystal Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.

Krystal Biotech Stock Performance

KRYS stock opened at $160.83 on Friday. The stock has a fifty day moving average of $180.46 and a 200-day moving average of $185.00. Krystal Biotech, Inc. has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of 90.86 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue was up 879.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.67) earnings per share. Equities analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Summit Trail Advisors LLC bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $1,893,000. Swiss National Bank raised its stake in Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after purchasing an additional 2,900 shares in the last quarter. Sei Investments Co. lifted its position in Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after purchasing an additional 6,363 shares during the last quarter. Shaker Investments LLC OH purchased a new position in Krystal Biotech in the 3rd quarter worth approximately $532,000. Finally, Citigroup Inc. increased its holdings in shares of Krystal Biotech by 65.4% in the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after buying an additional 13,874 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).